Below is a timeline which illustrates the over 40 years of clinical data on etifoxine and the evolution of GRX-917.

September 2018

May 2018

Compared etifoxine to lorazepam (Ativan®) – for alertness and cognitive functions in elderly patients

May 17, 2018|

Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet

November 2015

Safety Profile of Etifoxine: A French Pharmacovigilance Survey

November 13, 2015|

Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse or pharmacodependance were reported.

January 2015

March 2009

January 2006

Compared etifoxine to lorazepam (Ativan®) – established non-inferiority in adjustment disorder with anxiety ADWA

January 19, 2006|

Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin

April 2005